Radioiodine-Refractory Thyroid Cancer – Is it Time to Change the Definition in the Light of Novel Redifferentiation Therapies?

This webinar explores the perspectives on radiorefractory thyroid cancer through two presentations. In the first talk the speaker challenges current diagnostic frameworks and proposes a new vision that better reflects the evolving understanding of refractory thyroid cancer. The second presentation offers a comprehensive review of emerging approaches to restore iodine avidity in radiorefractory thyroid cancer, highlighting recent clinical trials, molecular targeting techniques, and potential promising combination therapies.

• To evaluate the current definition of radiorefractory thyroid cancer and identify its limitations in clinical practice
• To learn new insights for radiorefractory thyroid cancer definition and their potential impact on treatment decisions
• To learn current evidence-based redifferentiation strategies for restoring iodine avidity in radiorefractory thyroid cancer
• To improve knowledge of redifferentiation mechanisms to develop personalized treatment plans for patients with radiorefractory thyroid cancer

• Nuclear Medicine physicians, Endocrinologist, Oncologist